Closing Date 19/11/2018, 23:55
Type of Contract
Hours per Week
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top four cancer centres globally.
The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.
The Cancer Research UK Cancer Therapeutics Unit (CTU) within Division of Cancer Therapeutics is ranked among the world’s best academic cancer drug discovery and development groups. Led by Professor Raj Chopra, CTU is a multidisciplinary ‘bench to bedside’ centre, comprising around 170 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. Its 12 research teams cover every aspect of new drug discovery and development, from cell and molecular biology through to chemical synthesis of new agents and their evaluation in clinical trials.
CRUK CTU now seeks to appoint a Team Leader in Medicinal Chemistry who will lead an independent chemistry research team that will contribute to the overall strategy and goals of the CTU. Reporting to the Unit Director Professor Raj Chopra and the Head of Chemistry Professor Ian Collins, the focus of the successful appointee will be on designing and synthesising compounds that meet the objectives of one or more of CTU’s drug discovery projects with the primary goal of optimisation and progression of innovative small molecules to proof-of-concept clinical trials. Commitment to translational and drug discovery research is fundamental to this position.
The successful candidate will be an established researcher with a strong background in medicinal chemistry and drug discovery with the demonstrable ability to develop a research programme aligned with the overall research strategy of CTU. With the opportunity to appoint a number of core-funded scientists to their team, s/he will have an international research reputation and the proven leadership skills to manage and mentor a multidisciplinary project team. Knowledge of cancer biology and a track record of innovation in drug discovery, chemical biology or new technologies are essential. S/he will have the drive and ability to publish high quality research in leading chemistry, medicinal chemistry, computational chemistry and/or chemical biology journals, and significant experience of successfully securing research funding in the academic or commercial sector.
An executive search exercise is being undertaken by Perrett Laver to assist the recruitment committee. For informal inquiries please contact Dr Dr Goran Gregorovic at email@example.com or +44 20 7340 6202. For further details and to apply please click below.
Applications should consist of a letter of motivation and a complete curriculum vitae including a publication and research funding list and a PDF of up to 5 publications relevant to your research. The closing date for applications is Monday 19th November. Applications will be considered by the recruitment committee in late November and shortlisted candidates will subsequently be invited for campus visits and first stage interviews with representatives from the Division of Cancer Therapeutics in December. Final interviews will take place in early 2019
We consider all applications on merit and have a strong commitment to enhancing the diversity of our staff. We particularly welcome applications from women and people from ethnic minorities, as they are under-represented at the ICR at this level.